Recent Updates
Recently added Catalysts

Small Cell Lung Cancer Extensive Stage: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$16.1Buniverse median $1.20B
Allocated capital$1.1B$16.1B competing
Phase 3 or filed00 mid, 1 early
Pure plays0this indication only
Capital rank136/299crowding rank 151

Small Cell Lung Cancer Extensive Stage is uncontested. Jazz Pharmaceuticals (JAZZ) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Lurbinectedin in phase 1.

There is no public comparable to price it against. JAZZ spreads its $16.1B market cap across 14 indications, so $1.1B of it is allocated here.

Nothing here has reached Phase 3: 0 programmes in mid stage and 1 in early stage, so the field is still several years from a first approval.

$1.1B of allocated capital sits in Small Cell Lung Cancer Extensive Stage, ranking it 136th of 299 indications by the money committed to it.

Companies developing drugs for Small Cell Lung Cancer Extensive Stage 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
JAZZJazz PharmaceuticalsLurbinectedinPhase 11$16.1BNo14 30 Sep 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Small Cell Lung Cancer Extensive Stage counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Small Cell Lung Cancer Extensive Stage has one competitor and a median of $16.1B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

HER2 Positive Metastatic Breast Cancer1 company · $1.1B · median $16.1BUncontestedGastroesophageal Junction Adenocarcinoma1 company · $1.1B · median $16.1BUncontestedCNS Lymphoma1 company · $1.1B · median $16.1BUncontestedDiffuse Midline Glioma1 company · $1.1B · median $16.1BUncontestedH3 K27M Mutant Glioma1 company · $1.1B · median $16.1BUncontestedEsophageal Squamous Cell Carcinoma1 company · $1.2B · median $3.5BUncontestedMyelofibrosis3 companies · $1.3B · median $1.8BConcentrated betEpithelial Ovarian Carcinoma1 company · $1.3B · median $2.6BUncontested

Small Cell Lung Cancer Extensive Stage pipeline questions

Which biotech companies are developing drugs for Small Cell Lung Cancer Extensive Stage?

Jazz Pharmaceuticals (JAZZ, Lurbinectedin, Phase 1). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Small Cell Lung Cancer Extensive Stage.

How advanced is the Small Cell Lung Cancer Extensive Stage pipeline?

Of the 1 clinical-stage programme in Small Cell Lung Cancer Extensive Stage, 0 are in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Is anyone else developing a drug for Small Cell Lung Cancer Extensive Stage?

No. JAZZ is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Small Cell Lung Cancer Extensive Stage, which is why the indication is classified as uncontested.

When is the next Small Cell Lung Cancer Extensive Stage catalyst?

The next dated catalyst in Small Cell Lung Cancer Extensive Stage is JAZZ on 30 Sep 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map